2.39
0.00
(0.00%)
May 23 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 2.30 - 2.41 |
| 52 week | 1.97 - 8.72 |
| Open | 2.37 |
| Vol / Avg. | 0.00/320,820.00 |
| Mkt cap | 150.08M |
| P/E | - |
| Div/yield | - |
| EPS | -1.90 |
| Shares | 62.80M |
| Beta | - |
| Inst. own | 67% |
Events
Mar 25, 2013
Q4 2012 Horizon Pharma Inc Earnings Release
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -241.75% | -447.20% |
| Operating margin | -202.20% | -401.76% |
| EBITD margin | - | -373.55% |
| Return on average assets | -48.88% | -59.51% |
| Return on average equity | -93.57% | -115.60% |
| Employees | 247 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 520, 520 Lake Cook Road
DEERFIELD, IL 60062
United States - Map
+1-224-3833000 (Phone)
+1-224-3833001 (Fax)
DEERFIELD, IL 60062
United States - Map
+1-224-3833000 (Phone)
+1-224-3833001 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Horizon Pharma, Inc. operates as a biopharmaceutical company. It is focused on developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.
Officers and directors
| Timothy P. Walbert | Chairman of the Board, President, Chief Executive Officer | |
| Robert J. De Vaere | Chief Financial Officer, Executive Vice President | |
| Jeffrey W. Sherman M.D. | Chief Medical Officer, Executive Vice President - Development, Regulatory Affairs, Manufacturing | |
| Todd N. Smith | Executive Vice President, Chief Commercial Officer | |
| Michael G. Grey | Lead Independent Director | |
| Jeffrey W. Bird M.D., Ph.D. | Independent Director | |
| Jean-Francois Formela M.D. | Independent Director | |
| Jeff Himawan Ph.D. | Independent Director | |
| Ronald E. Pauli | Independent Director |